Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Glucagon for Injection (Eli Lilly) and GlucaGen® (Novo Nordisk) Administered by Subcutaneous and Intramuscular Injection in Normal, Healthy Volunteers

Trial Profile

Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Glucagon for Injection (Eli Lilly) and GlucaGen® (Novo Nordisk) Administered by Subcutaneous and Intramuscular Injection in Normal, Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Glucagon (Primary) ; Glucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Biodel
  • Most Recent Events

    • 07 Apr 2015 New source identified and integrated (ClinicalTrials.gov ; NCT02403648).
    • 16 Mar 2015 Status changed from recruiting to completed, according to a Biodel media release.
    • 16 Mar 2015 Primary endpoint has been met (pharmacokinetic and pharmacodynamic parameters to determine bioequivalence of glucagon delivered by the Glucagon Emergency Management system to marketed glucagon products), according to a Biodel media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top